Accelerating Research on ME/CFS
Total Page:16
File Type:pdf, Size:1020Kb
Accelerating Research On ME/CFS Summary of the NIH meeting.... and reflections on how far we’ve come and still have to go Anthony L. Komaroff, MD Brigham and Women’s Hospital, Harvard Medical School April 5, 2019, National Institutes of Health No significant conflicts of interest Mid-1980’s: Where Were We? An illness characterized by only symptoms and no consistent objective abnormalities: • No consistent physical exam abnormalities • No diagnostic tests • No proven treatments • No information on prognosis • No evidence of underlying biological abnormalities Hence, a suspect illness 2019: Where Are We? 2019: Where Are We? Cases differ from healthy controls (and sometimes disease comparison controls): • Central and autonomic nervous system • Metabolism (particularly energy metabolism) • Immune phenotype and function • Microbiome (?) • Gene structure, gene expression and other epigenetic differences (?) 2019: The Questions Going Forward • What causes the symptoms of the illness? • What causes the abnormalities in various systems? • What links together these different abnormalities? And what triggers them? • Is there a hypothetical disease model that fits with the abnormalities reported? Agenda for this Talk • Summarize data presented at this conference, and in prior literature, regarding the various abnormalities that have been reported • Consider several alternative models that might explain much of the data Neurologic Changes Structural & functional brain imaging Autonomic abnormalities CNS Involvement in ME/CFS • Neuroendocrine dysfunction: Impairment of multiple limbic-hypothalamic-pituitary axes (involving cortisol, prolactin, & growth hormone) and serotonin (5-HT) system • Cognition: Impairments in information processing speed, memory and attention — not explained by concomitant psychiatric disorders • Autonomic dysfunction: Impaired sympathetic and parasympathetic function, 30-80% • MRI: Multiple anatomic and functional abnormalities • SPECT: Areas of reduced signal • PET: Immune cell activation (neuroinflammation) • EEG abnormalities: sharp/spike waves, distinctive spectral coherence pattern, impaired connectivity PET Evidence of Brain Inflammation Distinguishes ME/CFS from Healthy P<0.001 CFS: N=9 Controls: N=10. From: Nakatomi Y, et al. J Nucl Med 2014; 55:945–950 MR Spectroscopy of the Brain Suggests Neuroinflammation • 15 women with ME/CFS and 15 matched healthy controls • Abnormalities were found in multiple brain regions, particularly left anterior cingulate • Metabolite ratios in 7 regions correlated with fatigue • Increased ratio of choline/creatinine, and increased lactate, were prominent findings From: Mueller C, et al. Brain Imaging and Behavior 2019; doi.org/10.1007/x11682-018-0029-4 Lactate in Spinal Fluid in ME/CFS: In vivo Proton MR Spectroscopy 0.86 ±0.5 90 80 P<0.001 for each, compared to ME/CFS 70 60 50 0.29 0.25 40 ±0.3 ±0.2 30 20 10 0 ME/CFS Anxiety Healthy Mathew SJ, et al. NMR Biomed 2008 (DOI 10.1002/nbm.1315) Conclusions •The majority of adult and all pediatric studies show OI is strongly associated with ME/CFS •Upright posture consistently aggravates ME/CFS symptoms, even in the absence of HR and BP changes •CBF reductions are substantial •Primary causes of OI in ME/CFS need further elucidation (auto-antibodies? MCAS? Vascular compliance in EDS?) •Open treatment of OI is associated with improvement in fatigue and other symptoms. More practical clinical trials needed. Even in ME/CFS patients with a normal HR and BP response during TTT: abnormal decrease of cerebral blood flow Courtesy of Peter Rowe, NIH, April 2019 Metabolic Changes Impaired ATP production Hypometabolism Oxidative/Nitrosative Stress Early Lessons From Metabolomics Studies employing optimal techniques (e.g., mass spect) for identifying levels of hundreds of metabolites in patients with ME/CFS compared to matched healthy controls • Levels of most metabolites are lower, as occurs in hibernation1 • Abnormalities incriminate impairment of cellular energy (regulated by the availability of NADPH) 1 and oxidative phosphorylation2 • Possibly a defect in one critical enzyme, pyruvate dehydrogenase3 • Defects in pathways converting sugars, lipids and amino acids into energy 1-5 From: 1Naviaux RK, et al. PNAS 2016;113:E5472-80; 2Tomas C, et al. PLoS ONE 2017;12(10):e0186802. 3Fluge O, et al. JCI Insight 2016;1:e89376; 4Yamano E, et al. Sci Rep 2016;6:34990; 5Germain A, et al. Mol BioSyst 2017;13: 371-379. Mitochondrial Damage to nucleic acids ↑ Anaerobic dysfunction and lipid membranes metabolism: ↑ lactate ↑ Oxidative Stress ↑ COX-2 ↓ antioxidant levels (Zn, DHEA, glutathione, vit E, CoQ10) ↑ peroxide & superoxide ↑ isoprostane & oxidized LDL ↓ α-tochopherol ↑ NFκB ↑ Nitrosative Stress ↑ iNOS, NO, nitrate, peroxynitrite ↑ iNOS ↑ IgM against nitro-[amino acids] Courtesy of Maureen Hansen, NIH, April 2019 Putative Targets 18 Cross referencing with PharmGKB database 242 gene-drug interactions 92 FDA-approved drugs affecting 39 targetable gene products Treatable targets in 37 of the 50 gene modules 23 identified to have a significant association with symptoms Including Adaptive Immune System, B-cell receptors, TNFa 11 targetable gene products show significant change from HC in ME/CFS NCOA1, UBE21, TRAF1, FKBP5, AHR, FYN, IKBKG, CASP9, CA9, DDIT3, CTNNB1 Jeffrey et al. "Treatment Avenues in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Split-gender Pharmacogenomic Study of Gene-expression Modules. Clinical Therapeutics. (in press) Based on the thirteen panels 43 CSF proteins were significantly different between the ME/CFS patients and matched controls with p-value <0.05. Generally increased levels of markers for neuroinflammation, cell damage and repair in ME/CFS patients. Both significant similarities and differences found when comparing ME/CFS and MS patients. Unpublished data Viral-Mitochondrial Connection • Mitochondrial architecture essential for innate immunity • Active (not latent) HHV-6 infection, at least in one cell line, fragments mitochondria • And inhibits ability of mitochondria to fuse • And reduces ATP production • Serum from ME/CFS fragments mitochondria, and removing serum resolves fragmentation Courtesy of Bhupesh Prusty, NIH, April 2019 Comparison of 20 CFS Cases and 20 Healthy Controls ) Zre ( N = Patients 20 (CCC) Controls 20 P = 1X 10-9 Impedance (Ohm) /Normalized to the Impedanceto baseline (Ohm) /Normalized Courtesy of Ronald W. Davis, NIH, April 2019 Immunologic Changes Lymphocyte phenotype and function Cytokines HLA Associations Highly simplified overview of the diverse stimuli and potential consequences of mast cell activation and secretion of cytokines, chemokines, and growth factors. Mukai K/Galli SJ. Immunological Reviews 2018; 282: 121–150 Immunological Abnormalities in ME/CFS • Increased levels of circulating immune complexes • Increased levels of immunoglobulin G • Decreased levels of certain IgG subsets • Increased numbers of CD8 + “cytotoxic” T cells bearing activation antigens (CD38 +, HLA-DR) • Poorly functioning natural killer (NK) cells • Increased blood levels of, and lymphocyte production of pro-inflammatory cytokines Cytokine Findings • Blood levels of many cytokines are significantly higher in ME/CFS patients than in healthy controls—in the first three years of illness, but not after1 • Levels of many cytokines in spinal fluid also distinguish patients from healthy controls2 • Levels of many circulating cytokines correlate positively with the severity of symptoms3 1Hornig M, et al. Science Advances 2015 (Feb 27);1:e1400121 2Hornig M, et al. Molecular Psychiatry (2016) 21, 261–269 3Montoya JG, et al. PNAS 2017;114:E7150-7158 Circulating Cytokines in ME/CFS Patients ❖ Innate (e.g. GM-CSF), adaptive (e.g. IFN--γ, IL-12), cross-talk (e.g. IL-17) immunity ❖ Th1 (e.g. IFN-γ), Th2 (e.g. IL-4, IL-5, IL-13), Th17 (e.g. IL-17) ❖ Leptin: perpetuation of inflammation, predominance in females, neuroinflammation ❖ TGF-β risk for non-Hodgkin’s lymphoma ❖ Of seventeen cytokines that correlated with severity, ten can be produced or induced by mast cells (Mukai K/Galli SJ. Immunological Reviews 2018; 282: 121–150) ❖ Mast cell: microglia interactions may influence neuroinflammation (Hendriksen et al, Neuroscience and Biobehavioral Reviews 2017 79:119-133) ❖ Could a central feature of ME/CFS be a dysregulated mast cell? CCL11, CXCL1, CXCL10, G-CSF, GM-CSF, IFN-γ, IL-4, IL-5, IL-7, IL-12p70, IL-13, IL-17F, leptin, leukemia inhibitory factor (LIF), nerve growth factor, stem cell factor (SCF), and TGF-α. HLA Associations • Association with ME/CFS: • ↑ risk: DRB4*01:01 (OR 2.30) • ↓ risk: C*05:01 (OR 0.60), DRBR*01:03 (OR 0.6) • Association with severe ME/CFS • ↑ risk: Four HLA factors (OR 3-4.4) • ↓ risk: One HLA factor (OR 0.38) Courtesy of Jose G. Montoya, NIH, April 2019 ME/CFS CD4 and CD8 T cell subset differences grouped by age Unpublished data, Courtesy of Derya Unutmaz, NIH, April 2019 Courtesy of Mark Davis, NIH, April 2019 Epigenetic Studies Epigenetic Changes in ME/CFS Comparing ME/CFS to healthy controls: • The DNA methylome is different, particularly with regard to glucocorticoid sensitivity genes1 and in genes important in cellular metabolism2 • Expression of microRNAs is different, particularly in natural killer cells3 • Difference in transcription factor levels: increased levels of NFĸB4 • Increased HDAC expression, leading to decreased gene expression5 1 deVega WC, et al. PLoS One 2014;9:e104757 2 deVega WC, et al. BMC Med Genomics 2017;doi 10.1186/ s12920-017-0248-3 3 Petty RD, et al.